-transparent.png){kind=logo}
Uroguanylin and guanylin are isolated mainly from the gastrointestinal tract and are activators of guanylyl cyclase C receptor (GC-C), which mediates the production of intracellular cyclic guanosine 3',5'-monophosphate (cyclic GMP). The bronchodilator effects of agents that raise cyclic GMP levels, such as atrial natriuretic peptide, have been reported, and uroguanylin mRNA has recently been detected in extra-gastrointestinal tissues, including the lung, suggesting their role in pulmonary activity. In the first step of this study, we examined the relaxant effects of uroguanylin and guanylin on isolated tracheal smooth muscle of guinea-pigs, and measured tissue cyclic GMP levels by means of enzymeimmunoassay. Uroguanylin produced concentration-dependent relaxant effects on resting tone and significant elevated cyclic GMP levels. Guanylin produced the same, but less potent, effects. In this study, we first investigated the effects of uroguanylin and guanylin on antigen-induced bronchoconstriction and airway microvascular leakage in actively sensitized guinea-pigs. Anesthetized male guinea-pigs, ventilated via a tracheal cannula, were placed in a plethysmograph to measure pulmonary mechanics for 10 min after challenging with 1 mg/kg of ovalbumin. Evans blue dye was then extravasated into their airway tissues to measure microvascular leakage. Intravenous pretreatment with uroguanylin significantly inhibited ovalbumin-induced bronchoconstriction and microvascular leakage in a dose-dependent manner. These inhibitory effects were mimicked by 8-bromoguanosine 3', 5'-cyclic monophosphate. This study is the first to show that uroguanylin not only had a potent bronchodilatory effect but also inhibited microvascular leakage. These results encouraged us to continue the above experimental and clinical studies in bronchial asthma.
H Ohbayashi, and
K Yamaki, and
R Suzuki, and
K Takagi
November 1992,
The American review of respiratory disease,
H Ohbayashi, and
K Yamaki, and
R Suzuki, and
K Takagi
August 1988,
The American review of respiratory disease,
H Ohbayashi, and
K Yamaki, and
R Suzuki, and
K Takagi
June 1997,
Arerugi = [Allergy],
H Ohbayashi, and
K Yamaki, and
R Suzuki, and
K Takagi
January 1992,
Life sciences,
H Ohbayashi, and
K Yamaki, and
R Suzuki, and
K Takagi
December 1995,
The Journal of allergy and clinical immunology,
H Ohbayashi, and
K Yamaki, and
R Suzuki, and
K Takagi
March 2005,
Pharmacology,
H Ohbayashi, and
K Yamaki, and
R Suzuki, and
K Takagi
November 1999,
Chinese medical journal,
H Ohbayashi, and
K Yamaki, and
R Suzuki, and
K Takagi
April 1998,
Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases,
H Ohbayashi, and
K Yamaki, and
R Suzuki, and
K Takagi
January 1996,
European journal of pharmacology,
H Ohbayashi, and
K Yamaki, and
R Suzuki, and
K Takagi
May 2001,
European journal of pharmacology,
